Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected.

As we moved from going to an office every day, to sheltering in place, the proliferation of web and video conferencing has exploded. Zoom parties and now even Hollywood entertainment are being presented via these platforms as people seek ways to stay connected virtually. But what happens after the lockdowns are lifted? What will agencies and clients do? Has our behavior changed for good? Is this the “new” normal?

LabCorp launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.

Shares of Fulcrum Therapeutics were up more than 14 percent after the company announced plans tol begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.

In the battle against COVID-19, the United States continues to see spikes in multiple states, and the nation’s top virus expert says the next few weeks will be critical to contain the spread of the disease that has caused the death of more than 121,000 Americans.

New information released by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19.

AstraZeneca signed a tenth supply-and-manufacturing deal for the company’s experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.

HyperPointe’s new CEO Ezra T. Ernst began his tenure with a pair of major moves: an agency relaunch and the signing of a new account focused on helping the country move forward from the COVID-19 pandemic.

Shares of Evelo Biosciences were up more than 25 percent after the company announced the investigational asset EDP1815 will be included in the Phase II/III TACTIC-E COVID-19-focused clinical trial for conducted by Cambridge University Hospitals NHS Foundation Trust.

As companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.